drugset / Trial / NCT00754221
Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a study to investigate the long-term safety and effectiveness \[S,S\]-Reboxetine in relieving the symptoms of Fibromyalgia in patients.
Timeline
- Start
- 2008-05
- Primary completion
- 2009-05
- Completion
- 2009-05
Outcome
Outcome not reported
Stopped: “This study has been terminated early as the esreboxetine development program is being discontinued. There are no safety or efficacy concerns.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [S,S]-Reboxetine | Unknown | 4 mg | Oral |
| Subject | [S,S]-Reboxetine | Unknown | 6 mg | Oral |
| Subject | [S,S]-Reboxetine | Unknown | 8 mg | Oral |
| Subject | [S,S]-Reboxetine | Unknown | 10 mg | Oral |